Greenphire Expands Global Travel Solution, ConneX
Greenphire has announced the expansion and growth of ConneX, a clinical trial travel solution designed to help meet the retention goals of global studies.
ConneX has expanded upon its in-market resources in key regions, including Japan, Central and Southern Europe, Scandinavia, and Southeast Asia.
In support of global trial retention, ConneX offers a host of personalized concierge services, including air, train, hotel, car services and rideshare, ambulatory care, and specialty services. This includes travel visa support, with successful applications recently processed for patients traveling from Jordan to Germany and Iraq to the USA.
Reference
Greenphire's ConneX Global Travel Solution Expands In-Country Support, Resulting in Significant Growth as Clinical Trial Travel Returns Post-Pandemic. (2023, February 28). Cision PR Newswire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
